Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Diagnosis and Treatment, Cancer Genomics and Diagnostics, and Lung Cancer Research Studies.
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Table S1 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Table S3 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Supplementary Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Data from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non-small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors.
Table S2 from Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in <i>RET</i>-Altered Solid Tumors: Analysis of the RETgistry Global Consortium
Taletrectinib in <i>ROS1</i> + Non–Small Cell Lung Cancer: TRUST
Taletrectinib in <i>ROS1</i>+ Non-Small Cell Lung Cancer: TRUST.
Pancancer outcome prediction via a unified weakly supervised deep learning model
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer.
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Return to Intended Oncologic Therapy in Patients With Metastatic Non-Small Cell Lung Cancer Discharged to a Skilled Nursing Facility.
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Novel radiogenomics approach to predict and characterize pneumonitis in stage III NSCLC
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
TRUST-II: a global phase II study of taletrectinib in <i>ROS1</i>-positive non-small-cell lung cancer and other solid tumors.
Modeling Costs and Life-Years Gained by Population-Wide Next-Generation Sequencing or Single-Gene Testing in Nonsquamous Non-Small-Cell Lung Cancer in the United States.
Clinical Nomogram Using Novel Computed Tomography-Based Radiomics Predicts Survival in Patients With Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.
Supplementary Data from Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers
Supplementary Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Data from Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers
Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Data from Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers
Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Supplementary Data from Novel Radiomic Measurements of Tumor-Associated Vasculature Morphology on Clinical Imaging as a Biomarker of Treatment Response in Multiple Cancers
Supplementary Data from Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation
Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer
Novel imaging biomarkers predict outcomes in stage III unresectable non-small cell lung cancer treated with chemoradiation and durvalumab.